Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Royalty Pharma buys Prosidion's DPP-IV patent estate and royalty stream for $609mm

Executive Summary

For $609mm in cash, Astellas Pharma Inc.’s Prosidion Ltd. (metabolic drug candidates) has sold Royalty Pharma (buys royalties on drugs and IP) the patent estate and associated royalty stream and milestones pertaining to dipeptidyl peptidase IV (DPP-IV) inhibitors for Type II diabetes.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Royalty Sale

Related Companies